Medicilon (688202): Won the bid for the procurement project of Zhejiang Provincial Tongde Hospital (Zhejiang Provincial Academy of Traditional Chinese Medicine), with a bid amount of 2.98 million yuan
I'm LongbridgeAI, I can summarize articles.Medicilon (688202) won the procurement project of Zhejiang Provincial Tongde Hospital, with an amount of 2.98 million yuan. The operating revenue in 2025 is 1.163 billion yuan, with a growth rate of 12.08%; the net profit is -168 million yuan, with a growth rate of 49.27%. In the first quarter of 2026, the operating revenue is 365 million yuan, with a growth rate of 36.52%; the net profit is 16 million yuan, with a growth rate of 207.35%
According to Tongbi Finance, data from Qichacha shows that, based on the "Announcement of the Bidding Results for the R&D Service Project of Antiasthma Class 1 New Drug Aerosol Formulation by Zhejiang Chengtao Bidding Agency Co., Ltd. for Zhejiang Provincial Tongde Hospital," Shanghai Medicilon Biopharma Co., Ltd. announced on May 28, 2026, that it won the procurement project for Zhejiang Provincial Tongde Hospital (Zhejiang Provincial Academy of Traditional Chinese Medicine), with a winning bid amount of 2.98 million yuan.
Related listed company: Medicilon (688202.SH)
Tongbi Finance Tip:
Medicilon (688202.SH) reported an operating income of 1.163 billion yuan in 2025, with an operating income growth rate of 12.08%. The net profit attributable to the parent company was -168 million yuan, with a net profit growth rate of 49.27%, and a return on net assets of -8.26%.
In the first quarter of 2026, the company's operating income was 365 million yuan, with an operating income growth rate of 36.52%. The net profit attributable to the parent company was 16 million yuan, with a net profit growth rate of 207.35%.
Currently, the company belongs to the healthcare industry, with main product types including chemical reagents, biological diagnostic reagents, and pharmaceutical distribution. The 2025 report indicates that the main business composition is: preclinical research: 50.72%; drug discovery and pharmaceutical research: 49.27%; other businesses: 0.01%.